This article is more than 5 years old. Information may no longer be current.
ER-positive, PR-positive breast cancer linked to increased risk for secondary primary cancer
Click Here to Manage Email Alerts
Women with early-stage breast cancer whose disease was ER-positive and PR-positive were at significantly increased risk for developing secondary primary cancers, according to the results of a prospective cohort study presented at the WIN Symposium.
The study included 19,580 women identified through the national cancer registry database in Taiwan. Researchers identified study participants between 2002 and 2006, and follow-up continued through 2008.
The rate of secondary primary cancers served as the main outcome measure.
Mean follow-up was 3.8 years, for a total follow-up period of 69,939 person-years. During that time, researchers identified 301 secondary primary cancers.
Researchers report a significant increase in leukemia and lymphoma (standardized incidence ratio=3.52; 95% CI, 1.97-5.81), as well as cancers of the corpus uteri (SIR=2.76; 95% CI, 1.77-4.11); stomach (SIR=2.64; 95% CI, 1.56-4.18); thyroid (SIR=2.56; 95% CI, 1.67-3.75); lung (SIR=2.28; 95% CI, 1.57-3.20); ovary (SIR=1.91; 95% CI, 1.04-3.21); and colon and rectum (SIR=1.63; 95% CI, 1.14-2.24).
Results of Cox proportional hazard regression models indicated that women with ER- and PR-positive breast cancer had significantly higher adjusted hazard ratios for secondary primary cancer incidence (P<.01).
Compared with women who had ER- and PR-positive breast cancer, the relative risk for secondary primary cancers were 0.39 (95% CI, 0.13-1.13) in women who were ER-negative/PR-positive; 0.76 (95% CI, 0.38-1.55) in women who were ER-positive/PR-negative; and 0.59 (95% CI, 0.37-0.95) in women who were ER- and PR-negative.
For more information:
Chen TI. Abstract #P1.12. Presented at: WIN Symposium; July 10-12, 2013; Paris.
Disclosure: The researchers report no relevant financial disclosures.